Child Immunization Schedule Addendum

Recommendations for Ages 18 Years or Younger, United States, 2025

Purpose

Outline new or updated vaccine recommendations that have occurred since October 24, 2024.

How to use the schedule

Vaccines and Other Immunizing Agents in the Child and Adolescent Immunization Schedule

To make vaccination recommendations, healthcare providers should:

  1. Determine recommended vaccine by age (Table 1 – By Age)
  2. Determine recommended interval for catch-up vaccination (Table 2 – Catch-up)
  3. Assess need for additional recommended vaccines by medical condition or other indication (Table 3 – By Medical Indication)
  4. Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
  5. Review contraindications and precautions for vaccine types (Appendix)
  6. Review new or updated ACIP guidance (Addendum)

Addendum

In addition to the recommendations presented in the previous sections of this immunization schedule, CDC has approved the following ACIP recommendations since October 24, 2024.

Vaccines Recommendations Effective Date of Recommendation*
Meningococcal (MenACWY-CRM/MenB-4C, Penmenvy) MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit in:
  1. healthy persons aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine and
  2. persons aged ≥10 years who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia)
 June 25, 2025
Influenza ACIP reaffirms the recommendations for routine annual influenza vaccination of all persons aged ≥ 6 months who do not have contraindications for the 2025-2026 season July 22, 2025
Influenza ACIP recommends only single-dose formulations of annual influenza vaccines that are free of thimerosal as a preservative for three populations:
  • Children 18 years or younger
  • Pregnant women
  • All adults
 July 22, 2025
RSV monoclonal antibody (Clesrovimab) ACIP recommends infants aged < 8 months born during or entering their first RSV season who are not protected by maternal vaccination receive one dose of clesrovimab. August 4, 2025
Note: As of May 29, 2025, the schedule incorporates the HHS directive regarding COVID-19 vaccine recommendations. (Changes were made to tables and notes for COVID-19 vaccines in pregnant women and children/adolescents ages 6 months through 17 years who are not moderately or severely immunocompromised).
*The effective date is the date when the recommendation was adopted and became official.
Print
Content Source:
National Center for Immunization and Respiratory Diseases